

PRODUCT INFORMATION




Gilteritinib

Item No. 21503

CAS Registry No.: 1254053-43-4
Formal Name: 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-2-pyrazinecarboxamide

Synonym: ASP2215
MF: C₂₉H₄₄N₈O₃
FW: 552.7
Purity: ≥98%
UV/Vis.: λ_{max}: 213, 314, 366 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Gilteritinib is supplied as a crystalline solid. A stock solution may be made by dissolving the gilteritinib in the solvent of choice, which should be purged with an inert gas. Gilteritinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of gilteritinib in ethanol and DMF is approximately 20 mg/ml and approximately 30 mg/ml in DMSO.

Gilteritinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, gilteritinib should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Gilteritinib has a solubility of approximately 0.125 mg/ml in a 1:7 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Gilteritinib is an inhibitor of FMS-related tyrosine kinase 3 (FLT3; IC₅₀ = 5 nM for the wild-type enzyme).¹ It inhibits mutant forms of FLT3, including FLT3 with the internal tandem duplication mutation (FLT3-ITD), FLT3-ITD expressing the F691L mutation, and FLT3 with various tyrosine kinase domain mutations (FLT3-TKD; IC₅₀s = 1.4-1.8, 12.2, and 0.7-2 nM, respectively). Gilteritinib also inhibits Axl and c-Kit with IC₅₀ values of 41 and 102 nM, respectively. It decreases the viability of blast cells isolated from patients with relapsed acute myeloid leukemia (AML) in a concentration-dependent manner. Formulations containing gilteritinib have been used in the treatment of AML.

Reference

1. Lee, L.Y., Hernandez, D., Rajkhowa, T., *et al.* Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. *Blood* **129**(2), 257-260 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/17/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM